GLP-1 Cost in 2026: Every Option from $50 to $1,349 per Month

Brand-name, compounded, oral, injectable, cash-pay, and insured — the complete pricing landscape for GLP-1 medications in 2026, with sources for every number.

GLP-1 medication pricing has changed dramatically in 2026. Medicare coverage launches in July, oral pills have created a new entry point, and cash-pay programs have expanded. But the spread between cheapest and most expensive remains enormous — from $50/month (Medicare Bridge) to over $1,300/month (retail list price). Here's what every option actually costs.

The Quick Reference: 2026 GLP-1 Pricing by Category

Medicare Coverage: The $50/Month Game Changer

The Medicare GLP-1 Bridge, launching July 1, 2026, is the single biggest pricing development in GLP-1 history. For the first time, Medicare Part D will cover weight-loss GLP-1 medications at a flat $50/month copay. CMS.gov

Eligible medications under the Bridge include Wegovy (all formulations, injection and oral), Zepbound (KwikPen formulation only), and Foundayo. The program runs through December 31, 2027, with a potential transition to the BALANCE Model for continued coverage. See our eligibility guide for the three-tier qualification criteria.

One important detail: the $50/month copay does not count toward your Part D annual out-of-pocket cap ($2,100 in 2026). The Bridge operates alongside your normal Part D coverage, not through it.

Oral GLP-1 Options: The New Entry Point

2026 is the year oral GLP-1s became commercially significant. Novo Nordisk's oral Wegovy (semaglutide tablet) launched with direct pricing at $149/month for the starting dose — making it the cheapest brand-name GLP-1 access point ever. Eli Lilly's Foundayo (orforglipron), approved in early 2026, is a once-daily oral pill that doesn't require the fasting-dosing protocol that made the diabetes version (Rybelsus) difficult for patients to follow.

Compounded GLP-1 Pricing: The Regulatory Context

Compounded semaglutide and tirzepatide remain available from licensed pharmacies, though the regulatory landscape has shifted significantly. The FDA ended the semaglutide shortage in February 2025 and the tirzepatide shortage in October 2024, which triggered enforcement timelines for compounding pharmacies under the 503A and 503B frameworks.

Prices for compounded formulations typically range from $149 to $449/month depending on the medication, dosage, and provider. These are not FDA-approved formulations, and each carries the required disclaimer that compounded medications are not FDA-approved. For a detailed breakdown of the compounding regulatory framework, see our 503A vs 503B explainer.

Insurance Coverage: The Wide Variation

Commercial insurance coverage for GLP-1 weight loss medications remains the biggest wildcard in pricing. As of 2026, an estimated 40–50% of employer-sponsored plans cover at least one GLP-1 for weight management, up from roughly 25% in 2024. However, coverage typically requires prior authorization, documented BMI meeting FDA thresholds, and sometimes evidence of previous weight loss attempts.

For type 2 diabetes, coverage is far more common — Ozempic and Mounjaro are on most commercial formularies for glycemic control, often with copays of $25–150/month. Some patients prescribed a GLP-1 for diabetes also experience weight loss as a secondary benefit, which does not require separate authorization.

Manufacturer Savings Programs